---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-160387"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2023-06-05T23:59:59+00:00"
generated_at: "2026-06-14T07:38:34.513000+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Phoenix Biotech Acquisition Corp. to merge with CERo Therapeutics in $50M deal

## Summary
- Consideration: ~5.0M shares of Class A common stock (value ~$50M) for CERo holders, plus up to 1.2M earnout shares.
- Closing condition: available cash after redemptions must be at least $30M; termination date Sept 30, 2023, extendable.
- Sponsor (699,996 Class A and 4,596,250 Class B shares) and CERo stockholders entered support agreements to vote in favor.
- Combined company renamed to 'CERo Therapeutics Holdings, Inc.' and will apply to list on Nasdaq.

## SEC filing metadata
- accession: 0001193125-23-160387
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2023-06-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000119312523160387/0001193125-23-160387-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000119312523160387/d494471d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-160387
- JSON: https://secwatch.observer/filing/0001193125-23-160387.json
- Plain text: https://secwatch.observer/filing/0001193125-23-160387.txt

## Key facts
- Material Agreements
  CERO THERAPEUTICS HOLDINGS, INC. entered into Business Combination Agreement with Phoenix Biotech Acquisition Corp., PBCE Merger Sub, Inc., and CERo Therapeutics, Inc. (effective 2023-06-04).
  - Action: entry
  - Agreement: merger
  - Counterparty: Phoenix Biotech Acquisition Corp., PBCE Merger Sub, Inc., and CERo Therapeutics, Inc.
  - Effective: 2023-06-04
  source text: On June 4, 2023, Phoenix Biotech Acquisition Corp., a Delaware corporation (the “ Company ”), entered into a business combination agreement and plan of reorganization (the “ Business Combination Agreement ”), by and among the Company, PBCE Merger Sub, Inc., a Delaware corporation (“ Merger Sub ”), and CERo Therapeutics, Inc., a Delaware corporation (“ CERo ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000119312523160387/0001193125-23-160387-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.